+ Stock options & sales commission
National travel up to 50%
Life science company democratizing access to advanced biological tools
Open for applications
Life science company democratizing access to advanced biological tools
201-500 employees
Open for applications
+ Stock options & sales commission
National travel up to 50%
201-500 employees
To empower the scientific community with more freedom and flexibility to accelerate our collective impact on humanity, and open the world of biology to new possibilities.
Element Bioscience specializes in advanced DNA sequencing and multi-omics technology. Its products offer powerful tools for researchers by combining various biological analyses into a single platform. Allowing scientists to examine DNA, RNA, proteins and other cellular components more efficiently and affordably.
The company aims to democratize access to these cutting-edge genomic tools, making high-quality, flexible and cost-effective solutions available to a broader range of researchers. By improving the accessibility and functionality of their technology, Element is accelerating scientific discoveries and enabling breakthroughs in understanding biological systems.
Element Bioscience has continued to expand through innovation and partnerships. In 2025, it announced a collaboration with SOPHiA GENETICS to combine AI-powered analytics with its sequencing systems, helping researchers generate insights more efficiently. The company has also introduced new technology, including the VITARI sequencing system, aimed at lowering the cost of whole genome sequencing and making advanced genomics more accessible to labs of all sizes.

Kirsty
Company Specialist at Welcome to the Jungle
Jul 2024
$277m
SERIES D
Jun 2021
$276m
SERIES C
Sorrento Mesa, San Diego, CA
Molly He
(CEO)Molly has more than 20 years of experience in technology innovation and management in the biotechnology and health industries. Previously a Senior Director of Scientific Research at Illumina, where they won the Innovation Award twice.
Michael Previte
(Co-Founder, CTO, SVP & R&D)Michael was previously an Associate Principal Scientist at Illumina. While there, they pioneered innovations in advanced sequencing technology for both single-molecular and ensemble-based methods.
Matthew Kellinger
(Co-Founder)Matthew earned their PhD in Biochemistry at the University of Texas at Austin. They previously worked as a Staff Scientist at Illumina where they focused on protein engineering to support and develop the future of genome sequencing.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
